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disease (PD). We evaluated the independent impact of dyskine-
sia on QoL in patients with PD and evaluated whether com-
monly used QoL instruments are sensitive enough to measure
dyskinesia effects in clinical trials. METHODS: We analyzed
data from the German PD Competence Network comprising
generic (EuroQoL [EQ-5D]) and disease-speciﬁc (PD Question-
naire 39 [PDQ-39]) QoL instruments and clinical variables
including the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS).
We used 4 dyskinesia-speciﬁc UPDRS items (i.e., duration, dis-
ability, painfulness of dyskinesias and presence of early-morning
dystonia) to predict totals and subscores of EQ-5D and PDQ-
39, values of the visual analogue scale (VAS) and EQ-5D derived
utilities. We performed ordinal logistic regression to predict EQ-
5D subscales and multiple linear regression to predict all remain-
ing QoL outcomes. Potential confounders were speciﬁed a priori
by an expert panel and ﬁnal confounders were selected based on
statistical criteria (univariate Spearman’s rank correlation, mul-
tivariate forward selection, p < 0.05). RESULTS: A total of 68
models were investigated (4 dyskinesia ¥ 17 QoL variables), of
which 9 showed a statistically signiﬁcant association after con-
trolling for confounding. The most relevant confounder was
severity of disease. All 4 dyskinesia variables were associated
with at least 1 QoL variable. Dyskinesia duration was shown to
be the most robust predictor. Subscales of EQ-5D and PDQ-39
addressing pain/(bodily) discomfort were associated with all 4
dyskinesia variables. In addition, EQ-5D index was associated
with duration of dyskinesia. CONCLUSIONS: Dyskinesia has a
signiﬁcant impact on QoL measured by EQ-5D and PDQ-39 and
their subscales, even after controlling for confounding. EQ-5D
and PDQ-39 are useful instruments for clinical trials addressing
questions on the effect of potential anti-dyskinesia treatments on
QoL.
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OBJECTIVES: Utility data is often needed in health economic
modeling, but not always available in clinical studies in Parkin-
son’s disease (PD). Therefore, we have recently presented a pre-
diction algorithm to estimate utilities from a clinical rating scale.
We now report effects of major complications in PD on this pre-
diction algorithm. METHODS: Data from an ongoing prospec-
tive cost study of the German Competence Network of
Parkinson Syndromes was used (n = 115). Our prior utility pre-
diction algorithm was exclusively based on subscales II–IV of 
the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS). Now, 
we applied multivariate regression analysis to investigate 
the independent effect of sociodemographic factors (age, sex), 
neuropsychological disturbances (depression, hallucinations,
dementia) and motor complications (falls, dyskinesia, ﬂuctua-
tions) on utilities measured by the EuroQoL (EQ-5D). Depres-
sion was evaluated by Beck’s Depression Inventory (BDI) and
dementia by Mini Mental State Examination. RESULTS: The
study population had a mean age of 67 years and was predom-
inantly male (67%). Mean EQ-5D was 0.74. Among all com-
plications investigated, only depression reached statistical
signiﬁcance (p = 0.03). UPDRS variables (subscores from part II,
III and IV) remained in the model (see equation): EQ-5D =
(103.23 - 1.29*UPDRS II - 0.30*UPDRS III - 1.23*UPDRS 
IV - 0.55*BDI)/100. After adjusting for UPDRS, depression
reduced the utility by 0.55 score units per BDI point. However,
the inclusion of BDI only marginally improved the explained
variance (adjusted R-square increased from 0.51 to 0.52). CON-
CLUSIONS: Whereas sociodemographic factors, motor compli-
cations and neuropsychological disturbances do not exert
independent effects on utilities when controlling for UPDRS,
depression has an independent effect on EQ-5D. Although
depression is not explicitly included in the UPDRS score of parts
II–IV, its inclusion did not substantially reduce the unexplained
variance. It remains to be investigated which factors further
explain the remaining variance.
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OBJECTIVES: The goal of this cross-sectional analysis was to
determine pain impact on Quality of Life (QoL) and interference
with disability among patients with chronic NeP. METHODS:
Participants in an observational, prospective and multicentre
study in Spain (DONEGA study) with NeP of different etiolo-
gies, completed the Short Form-McGill Pain Questionnaire (SF-
MPQ), the MOS Short Form-12 (SF-12), and the Sheehan
Disability Scale at baseline. RESULTS: A total of 1519 patients
[mean ± SD; 56.0 ± 13.7 years old (58.8% female)] with NeP
were enrolled in the study. Patients had NeP for 1.1 ± 2.8 years,
and 83.3% were on any type of analgesic treatment at baseline:
oral analgesics (51.2%), topical analgesics (26.9%), NSAID’s
(11.1%), antiepileptics (7.3%), and psychoanaleptics (3.5%).
Average Pain scores were 13.1 ± 8.2pts., 10.0 ± 5.8pts., and 3.1
± 3.3pts., for total scale (range 0–45), sensory domain (range
0–33), and affective domain (range 0–12), respectively. Present
pain intensity was 2.8 ± 1.0 (range 0–5) and mean pain past week
on a VAS scale was 71.2 ± 18.9mm. Pain substantially interfered
(≥5 on 0–10 scale) with normal work (6.0 ± 3.1), social life (5.7
± 3.0), and family life (5.3 ± 3.0), then producing disability;
Sheehan total (on 0–30 scale): 17.0 ± 8.4pts. Country normal-
ized physical (PCS) and mental health (MCS) component
summary scores (SF-12) indicated signiﬁcant impairment in both
domains compared to the general Spanish population: PCS; 37.6
± 6.0 vs. 50.1 ± 9.5, and MCS; 45.9 ± 8.1 vs. 50.0 ± 9.6, respec-
tively. Increasing levels of refractory pain, as assessed by number
of medications, corresponded to increasing levels of disability
(Sheehan total: 14.2 ± 8.8 to 16.4 ± 8.3, to 18.7 ± 8.1, and to
20.6 ± 7.0, by 0, 1, 2, and 3 medications respectively, p < 0.01
for all between group comparisons except 2 vs. 3). CONCLU-
SIONS: NeP decreases patients’ physical and mental components
of QoL, while increasing level of disability and impaired normal
work. The disability increases with level of pain treatment 
resistance.
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OBJECTIVES: The goal of this cross-sectional evaluation was to
assess pain impact and interference with mental functioning,
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symptom levels of anxiety and depression, and sleep impairment
among patients with NeP. METHODS: Participants in an obser-
vational, prospective and multicentre study in Spain (DONEGA
study) with NeP of different etiologies, completed the Short
Form-McGill Pain Questionnaire (SF-MPQ), the Mini Mental
State Examination (MMSE), the COVI Anxiety Scale, the
RASKIN Depression Rating Scale, and the MOS Sleep Scale
(MOS-S) at baseline. RESULTS: A total of 1519 patients above
18 years [mean ± SD; 56.0 ± 13.7 years old (58.8% female)] with
NeP were enrolled in the study. Peripheral NeP was presented in
>95.0% subjects. Patients had NeP for 1.1 ± 2.8 years, and
83.3% were on any type of analgesic treatment at baseline: oral
analgesics (51.2%), topical analgesics (26.9%), NSAID’s
(11.1%), antiepileptics (7.3%), and psychoanaleptics (3.5%).
Average Pain scores were 13.1 ± 8.2pts, 10.0 ± 5.8pts, and 3.1
± 3.3pts, for total scale (range 0–45), sensory domain (range
0–33), and affective domain (range 0–12), respectively. Present
pain intensity was 2.8 ± 1.0 (range 0–5) and mean pain past week
on a VAS scale was 71,2 ± 18,9mm. Pain slightly interfered with
patient mental functioning (average MMSE score; 27.2 ± 3.6pts,
18.0% of patients with MMSE score £ 24pts). Pain interfered
with all sleep attributes, obtaining high scoring in composite
measures; SLP6; 45.3 ± 21.8, and SLP9; 46.8 ± 21.1. The 24.4%
and 15.6% of patients had moderate to severe symptoms levels
of anxiety and depression (RASKIN and COVI scores ≥ 9 on
3–15 scale), with an average depression and anxiety scores of
6.3 ± 3.3pts and 5.4 ± 2.8, respectively. CONCLUSIONS: NeP
decreases patient mental functioning as assessed by MMSE,
while increasing anxiety and depression symptoms and sleep
problems. These ﬁndings substantially deteriorated with pain
severity.
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OBJECTIVES: Utilities for Parkinson’s Disease (PD) are needed
for cost-utility analyses of antiparkinsonian treatments but are
not always available from PD studies. We compared the perfor-
mance of classiﬁcation and regression tree (CART) analysis with
multiple regression for mapping the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) to utilities. METHODS: We used data
from an ongoing prospective cost study of the German Compe-
tence Network for Parkinson Syndromes. Single UPDRS items
were used as predictors for utilities assessed with EuroQoL (EQ-
5D). First, we developed a multiple regression model using
forward selection based on likelihood ratio testing (p < 0.05).
Second, we developed a CART model using t-test statistics as
selection criteria and adjusting p-values for non-dichotomous
variables by the Miller & Siegmund method. The resulting
mutual exclusive and exhausting groups were used as predictors
in a multiple linear regression model. The performance (good-
ness-of-ﬁt) of both approaches was compared using explained
variance (adjusted R-square statistic). RESULTS: The ﬁnal mul-
tiple regression model included a linear combination of three
UPDRS subscore variables (i.e., parts II–IV) and yielded an
adjusted R-square of 0.55. The ﬁnal CART model had three
levels with four variables partitioning the sample into ﬁve sub-
groups. These variables were level of rigidity (UPDRS item 22),
problems arising from a chair (item 27), posture (item 28), and
unpredictable ﬂuctuations (item 36). The mean (median) utility
in the 5 subgroups was 0.90 (0.89), 0.81 (0.89), 0.68 (0.70),
0.66 (0.70), and 0.32 (0.29). The CART model had adjusted R-
square of 0.50. CONCLUSIONS: Multiple regression performed
slightly better than CART when used to predict utilities based
on clinical characteristics of PD patients. Both models were
based on feasible and parsimonious prediction rules with only
three and four variables, respectively. Whereas multiple regres-
sion modeling is the more widely used statistical approach,
CART-based prediction models may be easier to interpret for
physicians.
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OBJECTIVES: We have recently reported on a generic, multi-
outcome disease model for Parkinson’s disease (PD). Now we
present ﬁrst results of internal, external and cross-model valida-
tion. METHODS: Our lifetime PD Markov model simulates a
hypothetical cohort of patients moving through health states
reﬂecting patient characteristics that would be observed in the
absence of treatment (Hoehn&Yahr “off” states [HYoff]). We
used HYoff I-V and death as Markov states. The model is
designed to simultaneously predict multiple outcomes, e.g. time
in Hoehn&Yahr “on” states (HYon) observed under treatment,
quality-adjusted life expectancy (QALE), or complication rates.
As internal validation, we compared time in HYoff stages pre-
dicted by our model to results reported in the progression study
used to derive our input parameters. As external validation, we
compared model results of mean times in HYoff and HYon states
with extern literature data not used in our model. Finally, we
cross-validated our model comparing QALE under levodopa
treatment with QALE of other published models reporting this
outcome. RESULTS: Internal validation of HYoff input data
showed a 97.4–99.9% accuracy. Although external validation of
average HYoff progression rates overestimated external popula-
tion data from Hoehn & Yahr (1967) by 19%, the mean HYon
progression rate predicted by our model (0.42 HY stages/y)
matched well with estimates reported in the literature (0.40 HY
stages/y). After restricting our model to a 5-year time horizon,
discounted QALYs exceeded those from 2 other published
models by 24% and 35%. This differences were mostly attrib-
utable to different Markov state-speciﬁc utilities. As other
Markov models for drug treatment did not evaluate QALE, we
could not cross-validate for this outcome. CONCLUSIONS: Our
PD model is internal valid and closely reproduces external data
for progression under standard treatment. Variability in QALE
are due to a combination of different model design, state-speciﬁc
utilities, and underlying study populations.
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